Covid-19 roundup: AlloVir snags IND approval for potential T cell therapy; Sanofi and GSK strike 300 million-dose deal with the EU
After snagging IND approval for its off-the-shelf virus-specific T cell Covid-19 therapy, AlloVir is now racing toward a proof-of-concept study …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
